Back to Search
Start Over
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53mutation
- Source :
- Blood; 20240101, Issue: Preprints
- Publication Year :
- 2024
-
Abstract
- •BOVen was safe and effective for the frontline treatment of TP53-mutant MCL.•The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy in TP53-mutant MCL.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs67802674
- Full Text :
- https://doi.org/10.1182/blood.2024025563